BRPI0309730A2 - antibody molecule, variant thereof, DNA sequence, expression or cloning vector, host cell, use of antibody molecule or DNA sequence, diagnostic or therapeutic composition, process for producing an antibody molecule, process for preparing of a diagnostic or therapeutic composition, and polypeptide - Google Patents
antibody molecule, variant thereof, DNA sequence, expression or cloning vector, host cell, use of antibody molecule or DNA sequence, diagnostic or therapeutic composition, process for producing an antibody molecule, process for preparing of a diagnostic or therapeutic composition, and polypeptideInfo
- Publication number
- BRPI0309730A2 BRPI0309730A2 BRPI0309730A BRPI0309730A BRPI0309730A2 BR PI0309730 A2 BRPI0309730 A2 BR PI0309730A2 BR PI0309730 A BRPI0309730 A BR PI0309730A BR PI0309730 A BRPI0309730 A BR PI0309730A BR PI0309730 A2 BRPI0309730 A2 BR PI0309730A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody molecule
- diagnostic
- dna sequence
- therapeutic composition
- antibody
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
molécula de anticorpo, variante desta, seqüência de dna, vetor de expressão ou clonagem, célula hospedeira, uso da molécula de anticorpo ou da sequencia de dna, composição diagnóstica outerapêutica, processo para a produção de uma molécula de anticorpo, processo para a preparação de uma composição diagnóstica ou terapêutica, e, polipeptídeo. são descritas moléculas de anticorpo contendo pelo menos uma cdr derivada de um anticorpo monoclonal de camundongo possuindo especificidade para cd22 humana. também é descrito um anticorpo enxertado com cdr no qual pelo menos uma das cdrs é uma cdr modificada. são adicionalmente descritas seqüências de dna codificadoras de cadeias de moléculas de anticorpo, vetores, células hospedeiras transformadas e usos das moléculas de anticorpo no tratamento de doenças mediadas por células expressando cd22.antibody molecule, variant thereof, DNA sequence, expression or cloning vector, host cell, use of antibody molecule or DNA sequence, outer therapeutic diagnostic composition, process for producing an antibody molecule, process for the preparation of a diagnostic or therapeutic composition, and polypeptide. Antibody molecules containing at least one cdr derived from a mouse monoclonal antibody having human cd22 specificity are described. Also described is a cdr-grafted antibody in which at least one of the cdrs is a modified cdr. DNA sequences encoding antibody molecule chains, vectors, transformed host cells, and uses of antibody molecules in the treatment of cd22-expressing cell-mediated diseases are further described.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0210121.0A GB0210121D0 (en) | 2002-05-02 | 2002-05-02 | Biological products |
| GB0210121.0 | 2002-05-02 | ||
| GB0393320 | 2003-05-02 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0309730A2 true BRPI0309730A2 (en) | 2019-03-12 |
| BRPI0309730B1 BRPI0309730B1 (en) | 2021-05-04 |
| BRPI0309730B8 BRPI0309730B8 (en) | 2021-05-25 |
Family
ID=67225936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0309730A BRPI0309730B8 (en) | 2002-05-02 | 2003-05-02 | antibody molecule having specificity for human cd22, DNA sequence, expression or cloning vector, host cell, use of the antibody molecule or DNA sequence, diagnostic or therapeutic composition, process for producing an antibody molecule, process for the preparation of a diagnostic or therapeutic composition |
Country Status (1)
| Country | Link |
|---|---|
| BR (1) | BRPI0309730B8 (en) |
-
2003
- 2003-05-02 BR BRPI0309730A patent/BRPI0309730B8/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0309730B1 (en) | 2021-05-04 |
| BRPI0309730B8 (en) | 2021-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0106682B8 (en) | antibody molecule, compound, DNA sequence, cloning or expression vector, host cell, process for producing the antibody molecule, therapeutic or diagnostic composition, use of the antibody molecule and use of the compound | |
| BR0212756A (en) | Antibody molecule having specificity for human kdr, antibody molecule variant, compound, DNA sequence, vector, host cell, process for producing the antibody molecule, therapeutic or diagnostic composition, and use of the antibody molecule | |
| ES2693596T3 (en) | Antibody that binds to human CD3 | |
| BR112019012040A2 (en) | isolated antibody or fragment thereof, composition, isolated cell, and methods for treating cancer, detecting cd73 expression in a sample and identifying a cancer patient suitable for treatment with an anti-cd73 therapy. | |
| AU675223B2 (en) | Chimeric multivalent protein analogues and methods of use thereof | |
| BRPI0407233A (en) | Neutralizing antibody, antibody molecule, cdr-grafted antibody, isolated dna sequence, cloning or expression vector, host cell, process for producing the antibody molecule, and, pharmaceutical composition | |
| BRPI0619595B8 (en) | neutralizing antibody, isolated DNA sequence, cloning or expression vector, host cell, process for producing an antibody, pharmaceutical composition, and use of a humanized neutralizing antibody | |
| CN110799539A (en) | Anti-4-1 BB antibodies and methods of making and using the same | |
| UA92580C2 (en) | Antibodies specific for human cd22 and their therapeutic and diagnostic uses | |
| BRPI0307837B8 (en) | anti-beta-a-4 peptide antibody molecule, compositions and their uses | |
| AR003423A1 (en) | HIGH-AFFINITY MONOCLONAL ANTIBODIES SPECIFIC OF RSV PROTEIN-F, TRANSFECTED EUCARYTIC CELLS; DNA SEQUENCE AND EXPRESSION VECTOR THAT CODES IT; METHOD USING THE ANTIBODIES; A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM; METHOD TO DETECT RSV AND A TEST KIT. | |
| BR9810907A (en) | Monoclonal and polyclonal antibodies, peptide capable of generating an antibody, immunogenic agent, nucleotide sequence, pharmaceutical composition, use of at least one antibody, diagnostic kit, and process for preparing an immunogenic agent | |
| BR0110927A (en) | Antibody, nucleic acid, vector, cell, method of making an antibody, pharmaceutical composition, use of an antibody or nucleic acid, and method for treating or prophylaxis of cancer | |
| NO953699D0 (en) | Isolated nucleic acid molecules encoding the tumor rejection precursor MAGE-3, as well as applications thereof | |
| AR046833A1 (en) | ANTI-INTERLEUQUINA ANTIBODIES-10 | |
| WO2003059951A3 (en) | Novel anti-igf-ir antibodies and uses thereof | |
| CN110121509A (en) | Neutralize anti-TL1A monoclonal antibody | |
| BRPI0712953B8 (en) | anti-nkg2a antibodies, their use, and pharmaceutical composition | |
| RS20050795A (en) | Recombinant antibodies and fragments recognising gangloside n-glycolyl-gm3 and use thereof in the diagnosis and treatment of tumours | |
| BRPI0806185A2 (en) | high-powered neutralizing antibody, antibody fragment, nucleic acid molecule, vector, cell, immortalized b-cell clone, epitope, immunogenic polypeptide, antibody production method, pharmaceutical composition, use of a first antibody or fragment, composition or use, method for treating a subject, kit for diagnosing hcmv infection, method for preparing a recombinant cell, method for producing antibodies, method for detecting polypeptides, and epitope specifically binding to an antibody | |
| CY1110848T1 (en) | NOGO HUMAN ANTI-ANTIQUE AND THE PHARMACEUTICAL OF THE USE | |
| CN118176215A (en) | Novel anti-L1 CAM antibodies | |
| BRPI0515893B8 (en) | human heat stress protein peptides, pharmaceutical composition, and, use of the peptide and pharmaceutical composition. | |
| BR0108654A (en) | Immunogenic composition, isolated polypeptide, expression vector or recombinant living microorganism, host cell, processes for producing an immunogenic composition and an immunogenic polypeptide or fragment thereof, use of a polypeptide or polynucleotide encoding a polypeptide, method for treatment of an individual by immunoprophylaxis or polypeptide therapy, antibody, agonist or antagonist, compound, and methods for diagnosing a disease or susceptibility to a disease and the presence of colorectal cancer or a susceptibility to colorectal cancer in an individual | |
| TW416960B (en) | Reshaped human antibody to human interleukin-8 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06H | Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette] |
Free format text: ANULADA PUBLICACAO 6.7 DA RPI 1878 DE 02/01/2007 POIS A MESMA FOI INDEVIDA. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: UCB S.A. (BE) |
|
| B25A | Requested transfer of rights approved |
Owner name: UCB PHARMA S.A. (BE) |
|
| B65X | Notification of requirement for priority examination of patent application | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/05/2003, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/05/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 02/05/2023 |